Travere Therapeutics, Inc.
TVTX
$14.50
$1.017.49%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 18.90% | 16.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.90% | 16.23% | |||
| Cost of Revenue | 21.23% | -5.47% | |||
| Gross Profit | 5.98% | 521.67% | |||
| SG&A Expenses | 5.92% | 1.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.78% | -1.85% | |||
| Operating Income | -5.90% | 16.44% | |||
| Income Before Tax | -10.04% | 21.18% | |||
| Income Tax Expenses | 14.29% | -198.82% | |||
| Earnings from Continuing Operations | -10.07% | 21.39% | |||
| Earnings from Discontinued Operations | 106.78% | 92.21% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.95% | 22.15% | |||
| EBIT | -5.90% | 16.44% | |||
| EBITDA | -5.48% | 21.02% | |||
| EPS Basic | -2.91% | 22.43% | |||
| Normalized Basic EPS | -0.82% | 20.91% | |||
| EPS Diluted | -2.91% | 22.43% | |||
| Normalized Diluted EPS | -0.82% | 20.91% | |||
| Average Basic Shares Outstanding | 6.85% | 0.36% | |||
| Average Diluted Shares Outstanding | 6.85% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
